dgd Research of San Antonio, Texas, now a member of Cetero Research, is conducting the Phase IIa, controlled US clinical trial. The trial will enroll a total of 21 diabetic patients at a single site measuring efficacy (using the gold-standard euglycemic-hyperinsulinemic clamping procedure), as well as pharmacokinetic parameters, safety and tolerability of AKP-020 in diabetic patients.
Jay Lichter, president and CEO of Akesis, said: “We are pleased to have reached this Phase IIa milestone. We are on track to complete enrollment and dosing according to schedule and anticipate announcing results when they become available.”